文献速递胸部肿瘤放疗放疗物理与技术

预测接受术后放疗的非小细胞肺癌患者重度急性放射性肺炎:基于临床与剂量体积直方图参数的列线图开发与内部验证

Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters.
PubMed 文献 · Radiother Oncol · 2018-10-29

研究收集2006至2017年间109例接受术后放疗的非小细胞肺癌患者的临床与剂量体积直方图参数,以术后放疗后3个月内发生重度急性放射性肺炎(≥3级)为终点构建列线图。多因素分析显示全肺平均剂量、同侧肺接受≥5 Gy体积百分比及同步放化疗为独立预测因素,列线图AUC为0.842,校准曲线与决策曲线分析显示良好一致性及临床净获益。

要点

  • 全肺平均剂量、同侧肺V5及同步放化疗是术后放疗后重度急性放射性肺炎的独立预测因素。
  • 基于上述三因素构建的列线图AUC为0.842,高于任一单一因素。
  • 列线图校准曲线显示预测值与实际观察值一致性良好,决策曲线分析显示多数阈值概率下净获益满意。

核心结论

  • 全肺平均剂量(>10.8 Gy)、同侧肺接受≥5 Gy体积百分比(>64.9%)及同步放化疗可预测接受术后放疗的非小细胞肺癌患者发生重度急性放射性肺炎。
  • 结合临床与剂量体积直方图参数首次构建并验证的列线图在临床实践中显示出潜在价值。

研究设计与样本

  • 回顾性收集2006至2017年间109例接受术后放疗的非小细胞肺癌患者的临床与剂量体积直方图因素。
  • 终点为术后放疗后3个月内发生重度急性放射性肺炎(≥3级)。
  • 采用逻辑回归评估各因素预测价值,基于多因素回归系数生成列线图,并通过ROC曲线下面积、校准曲线及决策曲线分析验证模型。

主要发现

  • 单因素及多因素分析显示全肺平均剂量(OR 1.003,95%CI 1.001-1.006,p=0.013)、同侧肺接受≥5 Gy体积百分比(OR 1.084,95%CI 1.020-1.151,p=0.009)及同步放化疗(OR 4.091,95%CI 1.331-12.572,p=0.014)为重度急性放射性肺炎的独立预测因素并纳入列线图。
  • 列线图AUC为0.842,高于全肺平均剂量(0.769)、同侧肺接受≥5 Gy体积百分比(0.744)及同步放化疗(0.661)任一单一因素。
  • 校准曲线显示预测的重度急性放射性肺炎与实际观察值一致性良好。
  • 决策曲线分析显示模型在多数阈值概率下具有满意的正向净获益。

关键数值与推荐

  • 全肺平均剂量>10.8 Gy、同侧肺接受≥5 Gy体积百分比>64.9%及同步放化疗可预测重度急性放射性肺炎。

临床怎么用

  • 作者认为结合临床与剂量体积直方图参数的列线图在临床实践中显示出潜在价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Postoperative radiotherapy (PORT) can potentially lead to radiation pneumonitis. We aim to develop a nomogram predicting the severe acute radiation pneumonitis (SARP, grade ≥3) in patients with non-small cell lung cancer (NSCLC) receiving PORT. MATERIALS AND METHODS: Clinical and dose-volume histogram (DVH) factors were collected from 109 patients between 2006 and 2017. The endpoint was the development of SARP within 3 months after PORT. Logistic regression was used to evaluate the prognostic value of each factor in predicting SARP. Nomogram was generated based on multivariate regression coefficients. Area under the ROC curve (AUC), calibration curves, and decision curve analyses (DCA) were conducted to validate the model. RESULTS: Univariate and multivariate analysis indicated that total lung mean dose (tlMD) (OR: 1.003, 95%CI: 1.001-1.006, p = 0.013), percentage of ipsilateral lung volume receiving ≥5 Gy (ilV5) (OR: 1.084, 95%CI: 1.020-1.151, p = 0.009), and concurrent chemoradiotherapy (CCRT) (OR: 4.091, 95%CI: 1.331-12.572, p = 0.014) were independent prognosticators of SARP and were included in the nomogram. ROC curves revealed the AUC of the nomogram was 0.842, which was much higher than any factor alone (tlMD: 0.769; ilV5: 0.744; CCRT: 0.661). Calibration curves showed favorable consistency between the predicted SARP and the actual observation. DCA showed satisfactory positive net benefits of the model among most of the threshold probabilities, indicating great clinical effect. CONCLUSION: We identified that the tlMD (>10.8 Gy), ilV5 (>64.9%), and CCRT could predict SARP among patients with NSCLC receiving PORT. Combining clinical and DVH parameters, a nomogram was first built and validated, showing its potential value in practice.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tang X, Li Y, Tian X, et al. Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters. Radiother Oncol. 2018. PMID: 30385172. doi:10.1016/j.radonc.2018.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。